Ainos Stock Soars 81% on $2.1M AI Nose Deal and VELDONA® Trial Approval

Introduction

Ainos, Inc. (NASDAQ: AIMD) is a dual-platform company combining artificial intelligence and biotechnology. Founded in 1984 on non-injectable interferon alpha technology, the company has evolved into a diversified medtech firm. Its core offerings include the AI Nose scent‐digitization platform and VELDONA®, a low-dose oral interferon program targeting human and animal diseases.

Corporate Structure and Experience

Headquartered in San Diego, California, Ainos employs between 11 and 50 people. Over nearly four decades, the company has amassed more than 60 patents and conducted over 60 interferon clinical trials. Ainos operates three business divisions—Pharmaceuticals, Medical Devices, and Preventive Medicine—each supported by over 100 scientific studies and strategic partnerships to advance diagnostic and therapeutic solutions globally.

AI Nose by Milad Fakurian

Developments and News

On August 6, 2025, Ainos shares closed at $4.22, representing an 81.12 percent increase, with a trading volume of 46,138,752 shares. On August 5, 2025, Ainos secured a $2.1 million order from ASE for deployment of its AI Nose platform in semiconductor manufacturing, marking a commercial sale in that sector.

In October 2024, the company announced developments in its AI‐powered electronic nose, which can detect 22 gases with 79 percent accuracy for applications in disease diagnosis, industrial safety, and robotics.

In July 2025, Ainos filed three Current Reports on Form 8-K disclosing (1) changes in certifying accountant (July 31, 2025), (2) amendments to its articles of incorporation (July 1, 2025), and (3) organizational updates (July 16, 2025).

Also in July 2025, Taiwan’s Food and Drug Administration approved a key clinical study of VELDONA® for primary Sjögren’s syndrome, with patient enrollment scheduled to begin in October 2025 under an open-label extension protocol.

Financial and Strategic Aspects

Ainos’s trading metrics indicate increased investor interest as it diversifies revenue streams beyond biotech into AI diagnostics. The $2.1 million ASE order supports the potential for future sales from industrial partnerships. VELDONA® has progressed through Phase II and Phase III trials for viral respiratory illnesses, Sjögren’s syndrome, and hepatitis C relapse prevention, while new programs are being developed for HIV-related oral warts and feline chronic gingivostomatitis. The company is focusing on scaling its SmellTech-as-a-Service and advancing interferon and SRNA pipelines toward commercialization.

Market Position and Industry Context

Ainos operates at the intersection of digital health, point-of-care testing, and sensory intelligence. Its AI Nose platform aims to enhance non-invasive diagnostics by digitally profiling volatile organic compounds, with applications in telehealth, long-term care, and automated manufacturing. In pharmaceuticals, the company utilizes decades of interferon research to support preventative medicine and animal health. As the telehealth and industrial automation sectors expand post-pandemic, Ainos is positioning itself as a provider of hardware-driven diagnostics and next-generation therapeutics.

tl;dr

On August 6, 2025, Ainos stock rose by 81.12 percent to $4.22 on a volume of 46.1 million shares. A $2.1 million AI Nose order from ASE was booked on August 5, 2025. Three Form 8-K filings in July 2025 disclosed changes in auditor and governance. Taiwan FDA approved VELDONA® for a Sjögren’s syndrome trial in July 2025, with enrollment set for October 2025. The company is working on commercializing AI-driven diagnostic devices while advancing low-dose interferon programs through clinical stages.